GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jinhe Biotechnology Co Ltd (SZSE:002688) » Definitions » EBIT

Jinhe Biotechnology Co (SZSE:002688) EBIT : ¥112 Mil (TTM As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Jinhe Biotechnology Co EBIT?

Jinhe Biotechnology Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ¥88 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ¥112 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Jinhe Biotechnology Co's annualized ROC % for the quarter that ended in Sep. 2024 was 4.45%. Jinhe Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 12.26%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Jinhe Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 1.63%.


Jinhe Biotechnology Co EBIT Historical Data

The historical data trend for Jinhe Biotechnology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jinhe Biotechnology Co EBIT Chart

Jinhe Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 281.52 201.25 146.84 128.72 92.42

Jinhe Biotechnology Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.94 -69.30 68.81 24.39 88.44

Competitive Comparison of Jinhe Biotechnology Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Jinhe Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jinhe Biotechnology Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jinhe Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Jinhe Biotechnology Co's EV-to-EBIT falls into.


;
;

Jinhe Biotechnology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥112 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jinhe Biotechnology Co  (SZSE:002688) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Jinhe Biotechnology Co's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=241.524 * ( 1 - 6.9% )/( (5090.925 + 5005.594)/ 2 )
=224.858844/5048.2595
=4.45 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5661.232 - 419.083 - ( 660.188 - max(0, 2025.363 - 2176.587+660.188))
=5090.925

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5737.89 - 374.682 - ( 841.97 - max(0, 1878.37 - 2235.984+841.97))
=5005.594

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Jinhe Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=353.756/( ( (2123.418 + max(794.706, 0)) + (2126.75 + max(724.275, 0)) )/ 2 )
=353.756/( ( 2918.124 + 2851.025 )/ 2 )
=353.756/2884.5745
=12.26 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(482.989 + 720.497 + 59.269) - (419.083 + 0 + 48.966)
=794.706

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(452.976 + 619.564 + 74.251) - (374.682 + 0 + 47.834)
=724.275

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Jinhe Biotechnology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=112.332/6904.688
=1.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jinhe Biotechnology Co EBIT Related Terms

Thank you for viewing the detailed overview of Jinhe Biotechnology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Jinhe Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
No. 71, Xinping Road, Inner Mongolia Autonomous Region, Tuoketuo County, Hohhot, CHN, 010200
Jinhe Biotechnology Co Ltd is engaged in manufacturing veterinary feed additives, veterinary vaccines, veterinary chemicals, corn starch processing and industrial wastewater treatments business.
Executives
Wang Zhi Jun Directors, executives
Liu Ying Chun Executives
Deng Yi Xin Secretary Dong
Li Fu Zhong Director
Liu Yun Tian Directors, executives
Xie Chang Xian Directors, executives
Wang Dong Xiao Director
Yao Jian Xiong Supervisors
Zheng Liu Ji Supervisors
Niu You Shan Executives
Wu Ming Xia Director
Li Wei Qi Directors, executives
Wu Rui Gang Executives

Jinhe Biotechnology Co Headlines

No Headlines